AI assistant
OnKure Therapeutics, Inc. — Director's Dealing 2021
Apr 8, 2021
34730_dirs_2021-04-08_1f746dee-1d7b-4d26-90fc-afed342d9034.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Reneo Pharmaceuticals, Inc. (RPHM)
CIK: 0001637715
Period of Report: 2021-04-08
Reporting Person: GREY MICHAEL G (Director, Executive Chairman)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 134084 | Indirect |
| Common Stock | 424601 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock option (right to buy) | $1.97 | 2028-04-04 | Common Stock (117406) | Direct | |
| Stock option (right to buy) | $3.76 | 2029-06-25 | Common Stock (32403) | Direct | |
| Stock option (right to buy) | $4.88 | 2031-01-20 | Common Stock (100563) | Direct | |
| Series A Preferred Stock | $ | Common Stock (20162) | Indirect |
Footnotes
F1: By Michael George Grey and Rondi Rauch Grey, Co-Trustees of The Grey 2014 Irrevocable Children's Trust u/a/d 12/17/14
F2: By The Grey Family Trust dated November 12, 1999
F3: All outstanding shares of Preferred Stock will automatically convert into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.